Journals / Solunum Hastalıkları / 2006 / Cilt: 17 - Sayı: 3

Exhaled nitric oxide levels in patients with bronchial asthma

Bronşiayal astımlı hastalarda ekspire edilen havadaki nitrik oksit düzeyi

Pages
105–110
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For this reason, measurement of exhaled NO level not only prevents missed diagnosis and incorrect treatment of bronchial asthma but also is useful to prevent all unnecessary spendings and loss of time.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Endogenous nitric oxide (NO) plays a highly significant role in the regulation of physiological and pathophysiological functions of the organism.
📊
Key Findings & Data:Material and Method: Forty-five bronchial asthma patients and 58 non-smokers subjects as a control group were inlucded in the study.
💡
Conclusion & Impact:For this reason, measurement of exhaled NO level not only prevents missed diagnosis and incorrect treatment of bronchial asthma but also is useful to prevent all unnecessary spendings and loss of time.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Yaş faktörü · Ekshalasyon · Astım

Abstract

Aim: Endogenous nitric oxide (NO) plays a highly significant role in the regulation of physiological and pathophysiological functions of the organism. The aim of this study was to determine the role of exhaled NO level for the diagnosis of asthma, severity of the disease, and following of the treatment. Material and Method: Forty-five bronchial asthma patients and 58 non-smokers subjects as a control group were inlucded in the study. Exhaled NO level was measured by chemiluminescence analyzer device with vital capacity manoeuvre. Results: Exhaled NO level was significantly higher in bronchial asthma group before the treatment than the healthy control group (21.6 ± 4.6 ppb versus 7.7 ± 1.8 ppb, p< 0.001). After the treatment of inhaled steroids, exhaled NO level has been significantly reduced and the difference was statistically significantly (21.6 ± 4.6 ppb versus 11.7 ± 1.8 ppb, p< 0.001). At the same time, exhaled NO level in the moderate persistan asthma group was significantly higher than in both mild persistan asthma group and control group (23.2 ± 4.8 ppb versus 19.6 ± 3.4 ppb, 7.7 ± 1.8 ppb, p<0.01). There is no correlation between exhaled NO level and atopy in bronchial asthma group. And also, we found no correlation between exhaled NO level and age, sex. Conclusion: Measurement of exhaled NO level has an important role for the diagnosis of asthma, severity of the disease and the following of treatment. In addition, measurement of exhaled NO level was non-invasive and easy applicable method. For this reason, measurement of exhaled NO level not only prevents missed diagnosis and incorrect treatment of bronchial asthma but also is useful to prevent all unnecessary spendings and loss of time.

Özet

Amaç: Endojen nitrik oksit (NO), organizmada birçok fizyolojik ve fizyopatolojik olayın regülasyonunda önemli bir rol oynar. Bu çalışmanın amacı; bronşiyal astımda ekspire edilen havadaki NO düzeyinin hastalığın tanısındaki yeri, hastalığın şiddetiyle ilişkisi ve tedavi sonrası oluşan değişiklikleri araştırmaktır. Gereç ve Yöntem: Çalışmamıza, 45 bronşiyal astımlı hasta ile kontrol grubu olarak sigara içmeyen sağlıklı 58 kişi alındı. Ekspire edilen havadaki NO düzeyleri vital kapasite manevrası ile bir kemiluminisans analizör cihazında ölçüldü. Sonuçlar: Bronşiyal astım grubunda tedavi öncesi ölçülen ekshale NO düzeyi kontrol grubundaki sağlıklı kişilerden anlamlı derecede yüksek bulundu (21.6 ± 4.6 ppb ve 7.7 ± 1.8 ppb, p< 0.001). Uygulanan inhaler steroid tedavi sonrası ekspire edilen havadaki NO düzeyi başlangıca göre belirgin olarak azaldı ve fark istatistiksel olarak anlamlı bulundu (21.6 ± 4.6 ppb ve 11.7 ± 1.8 ppb, p< 0.001). Ayrıca, orta persistan astım grubunda ekshale NO düzeyi hem hafif persistan astım hem de kontrol grubundan istatistiksel olarak anlamlı düzeyde yüksek olarak bulundu (23.2 ± 4.8 ppb ve 19.6 ± 3.4 ppb, 7.7 ± 1.8 ppb, p< 0.01). Bronşiyal astım grubunda ekspire edilen havadaki NO düzeyi ile atopi arasında bir ilişki bulunmadı. Ayrıca, ekspire edilen havadaki NO düzeyiyle yaş ve cinsiyet arasında bir korelasyon tespit edilemedi. Yorum: Ekspire edilen havadaki NO düzeyi ölçümü bronşiyal astım hastalığının tanısında, hastalığın şiddetinin değerlendirilmesinde ve tedavi takibinde önemli bir yere sahiptir. Ayrıca, inflamasyonun bir göstergesi olan ekspire edilen havadaki NO düzeyinin ölçümünün noninvaziv bir metod olması ve kolay uygulanabilirliği, bronşiyal astım hastalarının yanlış tanı ve tedavi görmelerini engellediği gibi boş yere yapılan tüm masrafları ve bu hastalık grubu için önemli olan zaman kaybını önlemek açısından da fayda sağlar.

🔖

Cite This Article

YURDAKUL, A. S., CANBAKAN, S., ÇAPAN, N., BAŞER, Y. (2006). Exhaled nitric oxide levels in patients with bronchial asthma. Solunum Hastalıkları, Cilt: 17 - Sayı: 3, 105–110. https://ajindex.com/articles/318498

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (20)

  1. Palmer RMJ, Ferrige AG, Monacada S. Nitric oxide release accounts for the biological activity of endotheliumderived relaxing factor. Nature 1987;327:524-6
  2. Lowenstein CJ, Snyder SH. Nitric oxide: A novel biological messenger. Cell 1992;70:705-7
  3. Kobzik L, Bredt D, lowenstein CJ, et al. Nitric oxide synthase in human and rat lung. Am J Respir Cell Mol Biol 1993;9:371-7
  4. Barnes PJ, Belvisi MG. Nitric oxide and lung disease. Thorax 1993;48:1034-43
  5. Zapol WM, Rimar S, Gillis N, et al. Nitric oxide and the lung. Am J Respir Crit Care Med 1994;149:1375-80
  6. Barnes PJ. Nitric oxide and airways. Eur Respir J 1993;6:163-5
  7. Barnes PJ, Liew FY. Nitric oxide and asthmatic inflammation. Immunology Today 1995;128-30
  8. Kharitonov SA, Yates D, Rubbins RA, et al. Increased nitric oxide in exhaled air of asthmatic patient. Lancet 1994;343:133-5
  9. Standarts for the diagnosis and care of patients with chronic pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44
  10. Global Initiative For Asthma. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report. National Heart, Lung and Blood Institute Publication Number 95-3659, January, 1995
  11. Kharitonov SA, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: Recommendations. Eur Respir J 1997;16:1683-93
  12. Robbins RA, Floreani AA, Von Essen SG, et al. Measurements of exhaled nitric oxide by three different techniques. Am J Respir Crit Care Med 1996;153:1631-5
  13. Kob H, Kalb-Bachofen V. Nitric oxide: A pathogenetic factor in autoimmunity. Immunology Today 1992;13: 157-60
  14. Barnes PJ, Kharitonov SA. Exhaled nitric oxide: A new lung function test. Thorax 1996;51:233-7
  15. Taylor DR, Poijnenburg MW, Smith AD, De Jongste JC. Exhaled nitric oxide measurements: Clinical application and interpretation. Thorax 2006;61:817-27
  16. Hamid Q, Springfall DR, Moreno VR, et al. Induction of nitric oxide synthase in asthma. Lancet 1993;150:1702-4
  17. Smith AD, Cowan JO, Filsell S, et al. Diagnosing asthma: Comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 2004;169:473-8
  18. Smith AD, Taylor DR. Is exhaled nitric oxide measurements a useful clinical test in asthma? Curr Opin Allergy Clin Immunol 2005;5:49-56
  19. Niskomp FF, Folkorts G. Nitric oxide and bronchial reactivity. Clin Exp Allergy 1994;24:905-14
  20. Türktaş H, Levent H, Oğuzülgen İK, Erbaş D. Effects of inhaled budesonide and nedocromil sodium on